Table 1 Patient characteristics

From: Patient-specific sequencing panels enable sensitive circulating tumor DNA analysis in rhabdomyosarcoma independent of genetic profile

Patient

Age (y)a

Sex

Subtypeb

Localization

Metastatic disease at diagnosis

Treatment protocolc

Genetic alterationsd

C001

9

m

Embryonal

Left cheek

No

CWS, SR, subgroup C

-

C002

8

f

Spindle cell

Left temporal region

No

CWS, HR, subgroup E/CWS 2007 HR/CWS ACCTIVE/RIST

MYOD1 p.L122R

C003

1

m

Embryonal (botryoid)

Floor urinary bladder

No

CWS, SR, subgroup D

-

C032

10

f

Alveolar

Nasal cavity/ ethmoidal cells

No

CWS, HR, subgroup G

PAX3/FOX01A

C047

15

m

Embryonal

Left testis

No

CWS, SR, subgroup C

 

C068

12

m

Spindle cell/Sclerosing

Below the left ear

No

CWS, HR, subgroup E

MYOD1 p.L122R

C076

15

m

Embryonal

Scrotum

No

CWS, SR, subgroup B

-

C077

4

f

Alveolar

Left side anterior chest wall

No

CWS, HR, subgroup G

PAX3/FOX01A

C090

4

f

Embryonal

Right cheek

Yes (BM)

CWS, HR, subgroup H/CEVAIE

-

C100

8

m

Embryonal (botryoid)

Roof urinary bladder

No

CWS, SR, subgroup D

-

C102

14

f

Alveolar

Left upper arm

Yes (lung, skeletal, BM)

CEVAIE/TECC/rEECur

PAX3/FOX01A

C123

6

f

Alveolar with neurogenic component/ ectomesenchymoma

Right side abdomen

No

CWS VAIA III

PAX7/FOX01A

  1. aAge at time of diagnosis.
  2. bClassification according to the World Health Organization.
  3. cTreatment protocol stratification according to the Cooperative Weichteilsarkom Studiengruppe (CWS) guidelines.
  4. dGenetic alterations detected in routine clinical diagnostic workup.
  5. BM bone marrow, HR high-risk, SR standard-risk.